2 completed, 2 recruiting, 1 not yet recruiting. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Lethargy: new trials by email Literature Review of Lethargy trials Research Report on Lethargy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy IRL757, Placebo - PARKINSON DISEASE (Disorder), Apathy | Phase 1 / Phase 2 | Recruiting | Integrative Research Laboratories AB | 75 | 2026-02-18 | 2026-09-03 |
| Accelerated rTMS vs. Sham for Stroke Apathy MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active), MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham), Brainsight Neuronavigation System - Apathy, Stroke | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 40 | 2025-08-08 | 2026-07-08 |
| Effort and Antidepressant Study Test Escitalopram 10mg, Placebo 10 mg - Effort Based Decision Making, Prosocial Behavior | Phase 1 / Phase 2 | Not yet recruiting | University of Oxford | 50 | 2025-01-01 | 2024-11-20 |
| Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers IRL757 - Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects, Apathy | Phase 1 | Completed | Integrative Research Laboratories AB | 12 | 2024-09-23 | 2026-02-05 |
| Accelerated rTMS for Post-Stroke Apathy MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System - Apathy, Stroke Sequelae | Phase 1 | Completed | Medical University of South Carolina | 21 | 2023-12-01 | 2026-07-10 |
Stroke (2) · Altruism (1) · Depression (1) · Ischemia (1) · Parkinson Disease (1)
Nervous System Diseases (5) · Neurobehavioral Manifestations (5) · Neurologic Manifestations (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Brain Diseases (3) · Central Nervous System Diseases (3) · Behavior (2) · Cardiovascular Diseases (2) · Cerebrovascular Disorders (2) · Vascular Diseases (2) · Basal Ganglia Diseases (1) · Behavioral Symptoms (1) · Movement Disorders (1) · Neurodegenerative Diseases (1)
Drug Delivery Systems (2) · Transcranial Magnetic Stimulation (2) · Escitalopram (1)
Integrative Research Laboratories AB (2) · Medical University of South Carolina (2) · University of Oxford (1)
United States (2) · Bulgaria (1) · Germany (1) · Poland (1) · Spain (1) · Sweden (1)
Catherine J Harmer, PhD (1) · Kevin Caulfield, PhD (1) · Lisa McTeague, PhD (1) · Parneet Grewal, MD (1) · Parneet Grewal, PhD (1)
PMID 15817019, PMID 16614016, PMID 1754629, PMID 19008681, PMID 20540829, PMID 20734360, PMID 26030001, PMID 26931289, PMID 28578330, PMID 42282206